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Increased invasiveness of MMP-9-deﬁcient tumors in two mouse
models of neuroendocrine tumorigenesis
K Shchors1,2, H Nozawa3, J Xu2, F Rostker2, L Swigart-Brown2, G Evan2,4 and D Hanahan1,3
Despite their apparent success in pre-clinical trials, metalloproteinase (MMP) inhibitors proved to be inefﬁcacious in clinical
settings. In an effort to understand the underlying causes of this unanticipated outcome, we modeled the consequences of
long-term MMP inhibition by removing one of the major players in tumorigenesis, MMP9, in two complimentary mouse models
of pancreatic neuroendocrine carcinogenesis: Myc;BclXl and RIP1-Tag2. By employing gel zymography and a ﬂuoregenic solution
assay, we ﬁrst established that MMP9 is expressed and activated in Myc;BclXl tumors in an interleukin-1b-dependent manner.
The genetic deletion of MMP9 in Myc;BclXl mice impairs tumor angiogenesis and growth analogous to its absence in the
RIP1-Tag2 model. Notably, tumors that developed in the context of MMP9-deﬁcient backgrounds in both models were markedly
more invasive than their typical wild-type counterparts, and expressed elevated levels of pro-invasive cysteine cathepsin B. The
increased invasion of MMP9-deﬁcient tumors was associated with a switch in the spectrum of inﬂammatory cells at the tumor
margins, involving homing of previously undetected, cathepsin-B expressing CD11b;Gr1-positive cells to the invasive fronts.
Thus, plasticity in the tumor inﬂammatory compartment is partially responsible for changes in the expression pattern of tumor-
associated proteases, and may contribute to the compensatory effects observed on MMP inhibition, hence accounting for the
heightened tumor progression described in late stage clinical trials.
Oncogene advance online publication, 5 March 2012; doi:10.1038/onc.2012.60
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INTRODUCTION
Matrix metalloproteinases (MMPs) are a family of zinc-dependent
proteinases that contribute to development and tissue homeo-
stasis, and modulate cancer progression by digesting a variety of
substrates. Owing to the role of MMP in extracellular matrix (ECM)
re-arrangement (also referred to as remodeling or degradation),
and in the promotion of neoangiogenesis, it was anticipated that
MMP inhibition in vivo would have an anti-tumorigenic effect.
However, phase III clinical trials with an MMP inhibitor (MMPI),
combined with standard-of-care chemotherapy, failed to demon-
strate clinical beneﬁt for late stage cancer patients and,
remarkably, was in some cases worse than the chemotherapy-
only control arm. For instance, the use of Bay 12-9566 in treating
patients with pancreatic cancer reduced both median progression-
free survival and quality-of-life when compared with standard care
gemcitabine.1 In another case, treatment of glioblastoma patients
rendered no statistically signiﬁcant survival beneﬁts.2 Additionally,
the clinical trials in small-cell lung carcinomas had to be
terminated prematurely.3 This failure led to the early cessation
of ongoing trials, and to reconsideration of the merit of a variety of
MMPIs in clinical development by a number of pharmaceutical
companies.4 - 6 The molecular mechanism behind this disappoint-
ing outcome of MMP inhibition is still unclear, given the
demonstrable efﬁcacy of MMPI in pre-clinical trials. The goal of
this study was to look for clues that might help explain the clinical
failure of MMPI.
Among candidate family members, we chose to focus on
MMP9. In humans, elevated levels of MMP9 expression and its
proteolytic activity correlate with poor prognosis in patients with
various types of cancer.7 - 9 Historically, increased MMP9 expres-
sion was viewed as a factor promoting tumor invasion.10 - 12
Subsequently, MMP9 was characterized as a potent trigger of
angiogenic switch in the genetically engineered mouse model of
pancreatic neuroendocrine carcinogenesis, RIP1-Tag2 (RT2).13,14
The pro-angiogenic capacity of MMP9 has also been observed in
other genetically engineered mouse models, including models of
cervical cancer,15,16 gliomagenesis,17 neuroblastoma18 and color-
ectal cancer.19 Both genetic ablation and pharmacological
inhibitors have been used to establish the role of MMP-9 in
tumor angiogenesis. Herein, we studied the effects of long-term
genetic deletion of MMP9 in two independent models of
pancreatic neuroendocrine tumorigenesis (PNETs)---RT2 and pIns-
MycERTAMRIP7-Bcl-xL (Myc;BclXl). The use of a gene knockout of
MMP-9 enabled us to avoid the complexities of pharmacological
agents, such as multiple targets, incomplete inhibition and
toxicity. We have previously characterized the angiogenic
phenotype in both the Myc;BclXl20,21 and the RIP-Tag2
models.13,22,23 Interestingly, the characteristics of tumor angiogen-
esis in the Myc;BclXl model, such as the release of sequestered
vascular endothelial growth factor (VEGF)-A to render it bioavail-
able to its receptors on endothelial cells, are similar to those in the
RT2 PNET model, suggesting that the regulation of tumor
angiogenesis during neuroendocrine tumorigenesis is indepen-
dent of initiating lesion. However, the contributing role, if any, of
MMP9 in the angiogenic phenotype of Myc-driven insulinomas
has not been established yet.
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We ﬁrst showed that MMP9 is expressed and functional during
the early stages of tumorigenesis in the Myc;BclXl model, and then
proceeded to investigate in further depth the characteristics of
tumors that have developed in the absence of MMP9 activity.
MMP9 deﬁciency in the Myc;BclXl model had a negative impact on
angiogenic switching during the initial stages of tumor progres-
sion, consistent with anti-angiogenic features of MMP9 deﬁciency
in the RT2 model. The advanced neoplastic lesions formed in
MMP9-deﬁcient animals in the Myc;BclXl and RT2 PNET models,
however, exhibited a profoundly invasive phenotype. A distinct
spectrum of inﬂammatory cells was found at the invasive margins
of MMP9-deﬁcient tumors in comparison with wild-type counter-
parts, involving the emergence of a sub-population of CD11b;
Gr1-positive cells that are characterized by the production of
pro-invasive cysteine cathepsin B.
RESULTS
MMP9 is rapidly induced and activated in response to c-Myc
The Myc;BclXl model of PNET, where 4-OHT-inducible c-Myc
expression is targeted to the b-cell compartment of pancreatic
islets, enables the different stages of tumorigenesis to be carefully
dissected. Myc is synchronously activated within 1--2 h in all
b cells following systemic administration of 4-OHT.20 To establish
whether MMP9 is present and functional during the early stages of
tumorigenesis in the Myc;BclXl model, we ﬁrst determined, using a
ﬂuorogenic solution assay, that daily activation of Myc for 3 days
induces MMP activity in islet tissue lysates (Figure 1a).
The analysis of a b-cell Myc target gene database obtained by
laser capture microdissection and mRNA proﬁling of Myc;BclXl
islets following 2, 8 and 24 h of Myc activation revealed that
genes encoding candidate MMPs (MMP2, MMP3 and MMP9) are
not direct transcriptional targets of Myc (Lawlor et al.24 and
Supplementary Figure 1a). However, MMP9 protease activity was
rapidly induced in islet tissue following Myc activation in vivo
(Figure 1a and Supplementary Figure 1b). The islets puriﬁed from
Myc;BclXl or BclXl animals treated in vivo with control vehicle and
4-OHT for 24 h (Myc-ON) were analyzed by gelatin zymography.
The induction of bands representing active and latent forms of
MMP9 was detected as early as 24 h following Myc induction. The
MMP9 origin of cleared regions on gelatin zymography gels was
conﬁrmed by comparing the activity proﬁle of treated Myc;BclXl
islets with the mobility of recombinant MMP9, and islets puriﬁed
from animals deﬁcient for MMP9 activity (Supplementary
Figure 1b). We did not observe any induction of proMMP2 or
activation of MMP2 (Figure 1b). Thus, despite the evidence that
Myc does not directly regulate transcription and production of
MMP9 in the Myc-expressing cancer cells, MMP9 induction in islets
was Myc dependent. In light of multiple studies, including in RT2,
which documented MMP9 expression by inﬁltrating immune
inﬂammatory cells,13,15 we assessed the possibility that MMP9 was
also supplied by innate immune cells in the Myc;BclXl model.
Myc induces MMP9 in leukocytes in an interleukin-1-b-dependent
manner
To determine the source of MMP9 production in neoplastic islet
tissue, we treated the Myc;BclXl animals for 3 or 7 days with 4-OHT
(Myc-ON), or control vehicle for 7 days, and analyzed tissue by
immunohistochemistry for MMP9 expression. Following activation
of Myc, MMP9 was increased in a subset of cells in the neoplastic
tissue (Figure 2a). Immunohistochemical analysis using the
leukocyte-speciﬁc marker CD45 conﬁrmed that the CD45þ cell
population is the source of MMP9 in this model (Figure 2b).
Although both CD68 and F4/80-positive cells were present in
abundance in islets in early stages of tumorigenesis, the majority
remained negative for MMP9 production (Supplementary Figure 2).
Previous immunohistological examination suggested that both
CD68þ and Gr1þ populations of the inﬂammatory compartment
of similar PNET tumors in the RT2 model express MMP9, with the
highest level of MMP9 expression associated with Gr1-positivity.
Similarly, the MMP9-expressing cells inside neoplastic lesions
driven by Myc are Gr1 positive (Figure 2c).
We previously demonstrated that the pro-inﬂammatory cyto-
kine interleukin (IL)-1b is rapidly upregulated and secreted in the
Myc;BclXL model.21 As IL-1b is known to recruit inﬂammatory cells
to tumor site,25 we reasoned that it might be involved in recruiting
and/or inducing the MMP9-expressing CD45þ leukocytes in the
Myc;BclXL model. We therefore performed gelatin zymograms on
neoplastic islets puriﬁed from Myc;BclXl animals subjected to
Myc-activation, in conjunction with control or IL-1b neutralizing
antibodies in vivo. Indeed, inhibition of IL-1b activity reduced
Myc-mediated induction of MMP9 (Figure 2d). Moreover,
immunohistochemical analysis using MMP9-speciﬁc antibodies in
Myc;BclXl pancreas in vivo conﬁrmed that MMP9 expression was
dependent on IL-1b activity. The treatment of Myc;BclXl animals
with 4-OHT (Myc ON) for 3 and 7 days combined with IL-1b
neutralizing antibodies resulted in a lack of induction of MMP9
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Figure 1. MMP9 is rapidly induced and activated in response to c-Myc. (a) Total gelatinase/collagenase activity (relative fluorescence units,
RFU) in the islets of Myc;BclXl animals untreated (d0) or Myc ON for 3 days (three mice per experimental group), as assessed by fluorogenic
solution assay utilizing quenched DQ-gelatin. Incubation of lysates with 1,10-phenanthroline (1,10-Phe) (þ , 4.0 mm) eliminated cleavage of the
fluorogenic substrate. Data reflect mean±s.e.m. (b) MMP9 activity was further visualized by gelatin zymogram assay. Protein lysates from
control Myc;BclXl islets, 24-h-treated Myc;BclXl islets or 24-h-treated BclXl islets were analyzed (three mice per experimental group). Cleared
region of gel indicating the presence of proMMP9, MMP9 and proMMP2 are shown.
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expression in vivo (Figure 2a). We conclude that MMP9 in the
Myc;BclXl model of carcinogenesis is provided by the inﬂammatory
cells and depends on Myc-induced IL-1b.
Loss of MMP9 activity affects the onset of angiogenesis
As IL-1b promotes Myc-induced angiogenesis by releasing ECM-
bound VEGF-A,21 it is plausible that MMP9, being a target of IL-1b
activity, is an intermediate effector of this process. To address this
possibility, we ﬁrst determined whether inhibition of MMP activity
affects Myc-induced VEGF-A release by Myc;BclXl islets. VEGF-A
levels were determined by enzyme-linked immunosorbent assay
in a medium conditioned by Myc;BclXl islets cultured in vitro with
control vehicle or 4-OHT for 3 days in conjunction with control
vehicle (dimethylsulphoxide) or a pan-MMPI (GM6001). Indeed,
Myc-induced VEGF-A release by islets was compromised by MMP
inhibition in vitro (Figure 3a).
To determine the biological signiﬁcance of MMP9 regulation
of VEGF-A levels in vivo, Myc;BclXl animals were crossed with
MMP9-deﬁcient animals. The resulting Myc;BclX:MMP9/ and
Myc;BclXl;MMP9þ /þ animals were treated with 4-OHT for 3 days
(Myc-ON). We previously demonstrated that endothelial cells in
Myc;BclXl islets start proliferating as early as 2 days following c-Myc
activation in vivo;21 thus 72h of Myc activation is an appropriate
time point to follow Myc-induced angiogenesis. The proliferative
status of the endothelial compartment in isolated pancreatic islets
was determined by analyzing co-expression of Meca-32 (an
endothelial cell-speciﬁc marker) and Ki67 (a proliferation marker).
We observed a delay in onset of angiogenesis in MMP9-null animals
compared with MMP9þ /þ (Figure 3b) and MMP9þ / littermates
(not shown). We next assessed VEGF localization in the Myc-OFF
pancreata vs pancreata collected from the animals following Myc
activation for 3 and 7 days. Although VEGF-A in Myc;BclXl;MMP9þ /þ
animals was released en mass from the ECM of pancreatic islets and
associated with the islet vessels, as demonstrated by its colocaliza-
tion with Meca-32 (yellow staining in panels v and vi, Figure 3c), a
substantial amount of VEGF-A in MMP9-deﬁcient islets was still
associated with ECM and not with the endothelium (red staining in
panels ii and iii, Figure 3c), much like in normal islets (Myc-OFF islets,
panels i and iv). The speciﬁcity of VEGF-A antibodies was conﬁrmed
by immunohistochemical analysis of RT2;RipCRE;VEGFAFlox/Flox
pancreata that lack expression of VEGF-A in islets (Figure 3c).23
Our data suggest that blood vessel formation in MMP9-deﬁcient
tumors differs in its characteristics from wild type, and is likely to be
less dependent on VEGF-A activity.
Loss of MMP9 activity promotes tumor invasion
Having established that MMP9 activity and involvement in VEGF
bioavailability is similar between Myc;BclXl and RT2 tumors, we
proceeded to investigate whether MMP9 activity affects tumor
progression. We ﬁrst focused on Myc-driven tumorigenesis. The
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Figure 2. Myc induces MMP9 in IL-1b-dependent manner. (a) Pancreata were harvested from the Myc;BclXl mice treated for either 3 or 7 days
with 4-OHT alone or in conjunction with AB-401-NA antibody (anti-IL-1b AB). For a Myc-negative control, mice were untreated (Myc OFF) or
treated with control vehicle in place of 4-OHT for 7 days. Bars, 20 mm. The panels are representatives of at least three animals assayed at each
data point, all analyses were done in duplicate; eight randomized fields per analysis were considered. (b, c) Immunohistochemical analysis for
MMP9 expression (green) in CD45-positive (b) or Gr1-positive (c) cells in tumor tissues from Myc;BclXl animals treated with 4-OHT daily for
3 days. The panels are representatives of three animals. Immunohistochemical analyses done in duplicate; 12 randomized fields per analysis
were considered. The tumor area is indicated by dotted line. The asterisks indicate the enlarged areas of the image. Bars, 25 mm. (d) Gelatin
zymogram assay for MMP activity in the Myc;BclXl islets collected from animals untreated (d0) or treated with 4-OHT in conjunction with
control (control IgG) or IL-1b neutralizing antibodies (anti-IL-1b) for the time specified (three mice per experimental group). Cleared region of
gel indicating the presence of proMMP9, MMP9 and proMMP2 are shown.
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animals from Myc;BclXl;MMP9KO and control Myc;BclXl back-
grounds were subjected to treatment with 4-OHT for 3, 7 and
21 days. Short-term Myc-activation in the Myc;BclXl model
promotes proliferation of b cells and the associated endothelial
cell compartment of pancreatic islets, while prolonged (21 days)
treatment results in tumor formation.20,21 Histopathological
analysis of pancreata by hematoxylin and eosin staining revealed
no gross pathological difference between control and MMP9-
deﬁcient islets in untreated and 3-day-treated samples (Supple-
mentary Figure 3). Surprisingly, however, the Myc;BclXl;MMP9-
deﬁcient tumors exhibited a heightened invasive phenotype, with
projections of cells extending into surrounding exocrine tissue
following just 1 week of Myc activation (Supplementary Figure 3),
which continued after long-term activation of Myc (Figure 4a and
Supplementary Figure 3).
We then asked whether the pro-invasion phenotype of MMP9-
deﬁcient carcinomas was a selective feature of Myc-driven
tumorigenesis, or a more general effect of MMP9 inhibition.
Similar analysis of the consequences of MMP9 loss in the RT2
model revealed that late stage RT2 tumors in MMP9-deﬁcient
animals also exhibited higher levels of invasiveness than
control counterparts (Figure 4b). The pancreata collected from
both Myc;BclXl (21-day-treated, long-term treatment) and RT2
(13 weeks, late stage tumorigenesis) animals from the MMP9/
background exhibit a 30% increase in tumors with a more
advanced invasion phenotype when compared with the corre-
sponding tumors from MMP9þ /þ and MMP9þ / backgrounds
(Figures 4c-- f). Tumor invasiveness was additionally scored based
on a circularity criterion. The MMP9-deﬁcient PNETs had more
irregular tumor borders than their wild-type controls as reﬂected
by decreased circularity (Figure 4g). In contrast, advanced MMP9-
deﬁcient tumors in both models were similar to their wild-type
counterparts in vascular network complexity, level of tissue
hypoxia and collagen IV coverage (Supplementary Figures 4
and 5).
Tumors developed from MMP9-deﬁcient background exhibit
increased activity of cysteine cathepsin proteases
Having established that loss of functional MMP9 results in the
formation of more aggressive lesions, we performed additional
analysis of MMP9-deﬁcient tumors, focusing on factors that might
explain the increase in tumor invasion.
It was recently demonstrated that members of the cysteine
cathepsin family promote invasion in the RT2 model,26 and thus
were plausible candidates. We ﬁrst determined whether total
cathepsin activity is increased in tumors developed from MMP9-
deﬁcient backgrounds. For this purpose, protein lysates were
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Figure 3. Loss of MMP9 activity affects onset of angiogenesis. (a) The pan-MMPI (GM6001) blocks Myc-induced release of VEGF from islets
in vitro. The islets isolated from the Myc;BclXl animals were treated in vitro with control vehicle or 4-OHT for 3 days in conjunction with control
vehicle (dimethylsulphoxide) or GM6001. Culture media were then collected, and VEGF-A levels were assayed by enzyme-linked
immunosorbent assay. The bars show VEGF-A induction by 4-OHT relative to samples treated with ethanol for 72 h. The data are re-
presentative of three independent experiments. (b) Immunohistochemical analysis of endothelial proliferation in vivo. The Myc;BclXl animals
from MMP9-deficient or MMP9 wild-type backgrounds were treated with 4-OHT for 3 days. Pancreata was isolated and analyzed by im-
munohistochemistry (IHC). Proliferating endothelial cells were identified by co-labeling with the endothelial marker Meca-32 (green) and Ki67
(red); nuclei are visualized with Hoechst dye (blue). The endothelial compartment of islets is indicated by asterisks. Bars, 50 mm. The
percentage of Meca-32-positive cells that also stained positive for the proliferation marker Ki67 was then determined as described in Materials
and methods section. ***Po0.0001 by Student’s t-test analysis. (c) MMP9 deficiency inhibits Myc-induced redistribution of VEGF-A in islets.
The Myc;BclXl animals from MMP9-deficient and wild-type backgrounds were treated with 4-OHT daily. As the times indicated, animals were
killed and pancreata isolated, sectioned and stained with anti-VEGF-A antibody (red) and Meca-32 (green). Areas of focal VEGF-A accumulation
are indicated by arrows. Bars, 50 mm. RT2;RipCRE;VEGF-A Flox/Flox pancreata is provided as a control for the VEGF-A antibody specificity. The
panels are representatives of at least three animals assayed at each data point, immunohistochemical analyses done in triplicate; 10
randomized fields per analysis were considered.
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prepared from freshly frozen tumor samples and incubated with a
speciﬁc biotinylated cathepsin activity probe as has been
described.27 The tumors collected from MMP9-deﬁcient back-
grounds had higher levels of cathepsin activity than tumors from
wild-type (Figure 5a) and MMP9þ / (Supplementary Figure 6)
counterparts.
We next performed western blot analyses to identify members
of cysteine cathepsin family that might be responsible for the
increased protease activity in the MMP9-deﬁcient samples. As
cathepsins C, S and B have been identiﬁed as major contributors
to tumor progression and tumor invasion,26 we at ﬁrst examined
their expression. We determined that cathepsin B (Figure 5b), but
not cathepsin S or cathepsin C (Figures 5c and d)---is signiﬁcantly
elevated in the tumors from MMP9/ background.
MMP9-deﬁcient tumors differ in their inﬂammatory proﬁle
It is well established that tumor invasion can in some cases
depend on the selective remodeling of ECM by proteases.28 Most
proteases involved in restructuring the ECM are supplied by the
inﬂammatory compartment.29 Correlation has been observed
between the type of inﬂammatory cells and the particular
secreted proteases that contribute to tumor progression.29
As MMP9-deﬁcient tumors are more invasive than their counter-
parts, we sought to determine the spectrum of inﬂammatory cell
types in MMP9-deﬁcient tumors.
Tumor-associated macrophages have been described as a
major source of cathepsin B in vivo,26 therefore we ﬁrst assessed
macrophage abundance using the macrophage-speciﬁc CD68
marker. Interestingly, we detected reduced numbers of CD68þ
macrophages in MMP9-deﬁcient lesions compared with
wild-type tumors in both the RT2 and Myc;BclXl models (Figures
6a and b). This result is consistent with prior studies demonstrat-
ing that the recruitment of macrophages can be MMP9
dependent.18,30,31
Depletion of macrophages provokes an inﬂux of other
leukocytes to the tumor site, whose recruitment is otherwise
inhibited by speciﬁc macrophage secreted factors.16 Therefore, we
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Figure 4. Loss of MMP9 activity promotes tumor invasion. Histopathological analysis by hematoxylin and eosin staining of pancreatic
neurodendocrine tumors from the Myc;BclXl animals treated with 4-OHT daily for 21 days (a) and from 13-week old RT2 animals (b), in both
cases that were either MMP9 wild type (WT), heterozygous (HET) or genetically deficient (KO). The asterisks indicate areas of tumor tissue
enlarged below. Bars, 75mm (a) and 100 mm (b). (c) Quantification of tumor invasiveness represented as the percentage of IT lesions or total IC
lesions (IC1þ IC2) in Myc;BclXl animals from different MMP9 backgrounds. A minimum of 51 tumors per group were graded. *Pp0.02 by
Fisher’s exact test. (IT, islet tumor; IC, invasive carcinomas; IC1, invasive carcinoma type 1; IC2, invasive carcinoma type 2). No statistically
significant difference was observed between MMP9 WT and MMP9 HET genotypes. (d) Same as (c) except IC lesions are separated into the IC1
and IC2 subclasses. *Po0.01 by the w2 test. (e) Quantification of tumor invasiveness represented as the percentage of IT lesions or total IC
lesions (IC1þ IC2) in RT2 animals from different MMP9 backgrounds. A minimum of 49 tumors per group were graded. *Po0.01 by Fisher’s
exact test. No statistically significant difference was observed between MMP9 WT and MMP9 HET genotypes. (f ) Same as (e) except IC lesions
are separated into the IC1 and IC2 subclasses. *Po0.01 by the w2 test. (g) Quantification of Myc;BclXl and RT2 tumor circularity from MMP9 WT
and MMP9 KO backgrounds. A minimum of 23 tumors per group were analyzed. **Po0.001, ***Po0.0001 by Student’s t-test.
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hypothesized that, in a similar manner, stromal cells of
non-monocytic lineage are predominant in MMP9-deﬁcient
tumors. To address the question, we assessed the presence of
various leukocytes using cellular antigen-speciﬁc markers. We
used CD3 (lymphocytes), CD4 (T-lymphocytes), Gr-1 (Ly6G-myeloid
differentiation antigen, present in bone marrow granulocytes
peripheral neutrophils, myeloid progenitors) and CD11b (Mac-1,
mainly myeloid cells) to visualize the respective cell types in the
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cathepsin S-specific antibodies. b-Actin was used as a loading control. Molecular weight markers are indicated. Quantification represents
expression relative to the MMP9 WT lane. (d) Western blot analysis of the RT2 MMP9 WT, MMP9 HET and MMP9 KO tumor lysates using
cathepsin C-specific antibodies. b-Actin was used as a loading control. Molecular weight markers are indicated. Quantification represents
expression relative to the MMP9 WT lane.
Figure 6. MMP9-deficient tumors differ in their inflammatory profile from wild-type counterparts (a) Quantification of inflammatory cells
recruited to the RT2 or to the Myc;BclXl tumor sites in MMP9 WT (blue) and MMP9 KO (orange) backgrounds. The data quantify CD68, CD4, Gr1
and Gr1/CD11b-positive cells as a percentage of total cells in the tumor tissue. P-values were determined by the Student’s t-test. *P-value of
Pp0.01 was considered significant. (b) Immunohistochemical analysis of CD68-positive cells (macrophages) in tumor tissues from the
Myc;BclXl animals treated with 4-OHT daily for 21 days, of from 13-week old RT2 animals, in each case in the context of MMP9 WT or MMP9 KO
backgrounds. Positive cells are indicated with arrows. Bars, 25 mm. (c) Immunohistochemical analysis of CD4-positive cells (red, T-lymphocytes)
in tumor tissues described above. Positive cells are indicated with arrows. Bars, 25 mm. (d) Immunohistochemical analysis of Gr1-positive cells
(red, myeloid differentiation antigen, present in bone marrow granulocytes and peripheral neutrophils) in tumor tissues described above. The
tumor invasion front is indicated by a dotted line. Bars, 50 mm (RT2 tumors) and 25mm (Myc;BclXl). (e) Representative images of Gr1 (green) and
CD11b (Mac-1) (red) cells in tumor tissues from RT2 animals of MMP9 WT and MMP9 KO backgrounds. The tumor invasion front is indicated by
a dotted line. The cells of myeloid origin co-express both the markers. The asterisks indicate the area of tumor represented in the insert on a
right upper corner. The insert shows staining for CD11b alone. Bars, 75 mm. (f ) Analysis of cathepsin B expression in Gr1-positive cells in tumor
tissues from the RT2 animals in the context of MMP9 WT or MMP9 KO backgrounds. The asterisks indicate the enlarged areas of the image that
show staining for cathepsin B (red) and Gr1 (green). Bars, 10 mm. (g) Same analyses as (f ) performed in tumor tissues from Myc;BclXl animals in
the context of MMP9 WT or MMP9 KO backgrounds. Bars, 25 mm. (h) Quantification of Gr1þ /cathepsin Bþ cells recruited to the RT2 or to
the Myc;BclXl tumor sites in MMP9 WT and MMP9 KO backgrounds. A minimum 27 tumors per group were analyzed. **One Gr1þ /cathepsin
Bþ cell was detected in the RT2;MMP9 WT tumors. *No Gr1þ /cathepsin Bþ cells were detected in the Myc;BclXl;MMP9 WT tumors.
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PNET tumors from MMP9þ /þ and MMP9/ backgrounds. We
observed a minor increase in the CD4þ fraction (Figure 6a).
However, the localization of CD4þ cells in tumors did not
correlate with the invasive front and, thus, these cells are unlikely
to contribute to the increased invasion of MMP9-deﬁcient lesions
(Figure 6c). On the other hand, Gr-1þ cells, whose recruitment to
the site of MMP9-deﬁcient tumors was also increased (Figure 6a),
were localized to the invasive front of the tumors (Figure 6d). The
majority of those cells were CD11b positive, suggesting their
myeloid origin (Figures 6a and e).
As pro-invasive cathepsin B was the differential factor present in
MMP9-deﬁcient tumors, we sought to determine the source of the
increased cathepsin B activity. Myeloid cells are reported to
express a spectrum of proteases including neutrophil elastase, a
known activator of cathepsin B activity.32,33 However, a western
blot analysis for neutrophil elastase expression in MMP9-deﬁcient
tumors showed no signiﬁcant induction of this protein when
compared with MMP9 wt counterparts (Supplementary Figure 7a).
Thus, there is no evidence linking neutrophil elastase and
cathepsin B activity in our model. The major source of cathepsin
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B in the RT2 model is CD68þ monocytes. Indeed, we detected
CD68þ cells expressing cathepsin B in tumors from both
backgrounds, but the total number of those cells was reduced
in MMP9-deﬁcient tumors (Figures 6a and b, or Supplementary
Figure 7b). Gr1þ cells, which are readily detectable in tumors
from both MMP9-deﬁcient backgrounds, do not express cathepsin B
in RT2;MMP9 wt and Myc;BclXL;MMP9 wt tumors (Gocheva et al.26
and Figures 5f --h). We therefore hypothesized that a distinct
subset of Gr1þ cells, recruited to the tumor site in the context of
reduced macrophage abundance, becomes an alternative source
of cathepsin B. Indeed, the analysis of cathepsin B expression in
the Gr1þ population of MMP9-deﬁcient tumors revealed that a
majority of Gr1þ cells localized to the invasive front of the tumors
were expressing cathepsin B in both RT2 and Myc;BclXl tumors
(Figures 6f --h). Thus, we establish that lack of MMP9 activity in two
independent models of carcinogenesis promotes tumor invasion,
and is associated with expression of pro-invasive cathepsin B by a
sub-population of Gr1þ cells.
DISCUSSION
The failure of MMPIs in clinical trials was originally attributed to
unspeciﬁc targeting, inefﬁcacy of drugs and the redundancy of
MMPs;5,34 in addition, the MMPIs were administered at the late
stages of tumor progression, when MMP activity is now known to
be less critical for tumor growth.4,5 It subsequently emerged that,
along with their originally described role as regulators of ECM
remodeling and facilitators of tumor growth, MMPs modulate the
activity of both inducers and inhibitors of tumorigenesis, by
processing cytokines, angiogenic and growth factors, and their
respective receptors, as well as altering cell adhesion and
stimulating epithelial to mesenchymal transition.35
We sought to investigate events behind inefﬁcacy of MMP
inhibition, focusing our analysis on MMP9, the key regulator of
tumor angiogenesis in various tumor models including the PNET
model-RT2.13,17,36,37 We established that, in a complimentary
model of PNET-Myc;BclXl-MMP9 promotes tumor angiogenesis as
well. The advantage of the Myc;BclXl model lies in the rapid and
highly synchronized onset of the disease exhibiting ‘hallmarks’ of
cancer progression such as angiogenic switching, inﬂammation
and invasion.20 MMP9 expression and proteolytic activity were
increased within the ﬁrst days of the Myc-induced neoplastic
progression, suggesting that this protease could be involved in
the early stages of tumorigenesis. Indeed, MMP9 deﬁciency
in the Myc;BclXl model had a negative effect on angio-
genic switching (Figure 3b), and promoted transient tissue
hypoxia (Supplementary Figure 5d). However, the advanced
Myc;BclXl;MMP9/ tumors that developed following 21 days of
Myc activation were well vascularized (Supplementary Figure 5c).
Concordantly, although the loss of MMP9 had a negative impact
on angiogenic switch in hyperplasias and dysplasias the RT2
model,13 the RT2;MMP9/ invasive carcinomas that subsequently
developed in RT2;MMP9/ mice were well vascularized. The
molecular mechanism by which the MMP9-deﬁcent tumors elicit
MMP9-independent angiogenesis in late stages of tumor progres-
sion is currently unclear. It is possible that transient tissue hypoxia
occurring during MMP9-deﬁcient tumor progression triggers this
adaptation, for example, by recruiting cathepsin-expressing
myeloid cells.25
The increased production and activation of MMP in tumors
observed in several other models of Myc-driven tumorigenesis
was attributed to the direct transcriptional regulation of MMP by
Myc in cancer cells.38 - 40 However, it is now well established that
MMPs supplied by inﬂammatory cells rather than by cancer cells
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themselves are major players in promoting tumorigenesis.14,18,37
Our data indicate that signaling between tumor cells and
the inﬂammatory compartment of the PNETs is mediated
by inﬂammatory cytokine IL-1b. A growing body of evidence
indicates that inﬂammatory cytokine IL-1b, which has an impor-
tant role in acute and chronic inﬂammatory diseases, might
mediate signaling between tumor and inﬂammatory cells.21,41,42
IL-1b orchestrates the expression of a variety of factors including:
growth factors,43 chemoattractants44 and matrix MMPs.45,46 Our
data suggest that IL-1b, which triggers the initial steps of Myc-
induced angiogenesis, mediates production of MMP9 in the
microenvironment of Myc;BclXl tumors. Moreover, elevated
expression of IL-1b was recently observed during angiogenic
switching in the RT2 model, making IL-1b a possible candidate in
promoting RT2 tumorigenesis (Sadanandam and Hanahan,
unpublished).
Despite the well-established pro-angiogenic and tumor-growth-
promoting role of MMP9, we found that genetic deﬁciency for this
protease contributed to the increased invasiveness of tumors both
in the Myc;BclXl and in the independent RT2 models of PNET. A
number of previous studies hinted that loss of MMP9 activity
might render more hostile tumors. For example, in the K14-HPV16
model of squamous skin carcinogenesis, while MMP9 deﬁciency
decreased the total number of tumors, the emerging tumors were
signiﬁcantly more aggressive than wt counterparts.36 Additionally,
MMP9-deﬁcient cancer cells exhibited increased invasiveness in a
glioblastoma model,17 an effect that was also witnessed in the
CR2-Tag model of prostate tumors.37 We observed that increased
invasion in the MMP9-deﬁcient cancers was associated with the
reduction of CD68þ cells, whose homing, at least in part, is
mediated by MMP9 proteolytic activity (for review, see Campbell
et al.30 and Deryugina and Quigley47). Interestingly, the decreased
percentage of CD68þ cells inversely correlated with the presence
of CD11bþ ; Gr1þ cells at the tumor margins. Notably, CD11b;
Gr1-positive cells have been increasingly implicated as facilitators
of tumor invasion and metastasis.48 - 50 There is a complex
crosstalk between CD68þ and CD11bþ ; Gr1þ cells in tumors.
For instance, in a mouse model of cervical carcinogenesis, the
impaired recruitment of macrophages resulted in increased
migration of neutrophils to the tumor site, because of the ablation
of neutrophil inhibiting factors normally secreted by those
macrophages.16 Moreover, MMP9 deﬁciency in the MMTV/neu
mouse model of mammary carcinoma is associated with the
depletion of tumor-associated monocytes, and increased inﬁltra-
tion of neutrophils (Werb, personal communication).
There are currently several hypotheses aiming to explain the pro-
invasive consequences of MMP inhibition. One possibility is that loss
of MMP9 activity results in retention of ECM-bound VEGF. The pro-
invasive and pro-metastatic potential of VEGF inhibitors was recently
described.51,52 Another is that deﬁciency in MMP activity in skin
tumors might reduce host defense by modulating chemokines and
cytokines.53,54 Herein, we present evidence that in PNETs the loss of
MMP9 activity in tumors is accompanied by a shift in the spectrum
of proteases toward expression of cysteine cathepsins, speciﬁcally
cathepsin B (in part supplied by CD11b; Gr1-positive cells), which
may provide compensatory protease activity.
The cysteine cathepsin family, which currently consists of 11
members,55 is predominately found inside the lysosomal compart-
ment of the cell. Several members also are released in the
extracellular space, and are involved in a variety of normal
physiological processes (for review, see Turk et al.56). In addition,
the abnormal expression and activity of some of the cysteine
cathepsins in lesions of different origin implicates these proteases
in promoting tumor progression.57 The expression of secreted
cysteine cathepsins has been associated with tumor progression
in several models of carcinogenesis including K14-HPV16-driven
cervical cancer,27 K-rasG12D lung adenocarcinomas,58 RT2 PNETs27
and Myc;BclXl PNETs (Shchors and Evan, unpublished). Upregula-
tion of six cathepsins (B, C, H, L, S and Z) was observed in the RT2
model;27 among them, cathepsins B and S supplied by
inﬂammatory cells demonstrably promoted tumor invasion.26,59
The exact mechanism by which cathepsin B contributes to
invasion is still under investigation. Cathepsin B is directly involved
in degradation of a variety of targets, including such ECM proteins
as ﬁbronectin, types I and IV collagen and laminin60 - 62 as well as
cell adhesion molecule E-cadherin.59 Although cathepsin B is
present and functional in the MMP9 competent tumors, we have
now established that the spectrum of cathepsin B producing cells
and the levels of cathepsin B are elevated on the loss of MMP9
activity. It was previously suggested that the source of protease
expression might affect not only the levels of the enzyme per
se but also its pro-tumorigenic activity.8,14 For example,
epithelial cancer cell versus stromal cell expression of MMP has
differential prognostic correlation with overall survival in cases of
epithelial ovarian cancer.8 The MMP and cathepsin families are
joined in a complicated network of protease activity in tissues (for
review, see Levicar et al.63). It is apparent that MMP9 and
cathepsin B differ in their pro-invasive capacity. For instance, in
the analysis of gastric carcinomas, high expression of cathepsin B,
but not MMP9, was a statistically signiﬁcant parameter in the
depth of tumor invasion.64 Interestingly, there are some indica-
tions that success of therapeutic trials targeting MMP activity is
linked to the lack of cathepsin B in the tumors. For example,
inhibition of MMP activity in renal cell carcinoma, a type of cancer
with exceptionally low levels of cathepsin B,65 was one of the rare
MMPI trials where the overall survival of the patients was
signiﬁcantly prolonged.66 Our results are consistent with the
initial observations that MMPs act mostly as regulators of tumor
angiogenesis,13,14 while cysteine cathepsins contribute to invasion
potential of the tumors.27,59 On inhibition of MMP activity, tumors
can evidently highjack the existing blood supply in an organ,17
possibly achieving the required increased migratory capacity by
engaging cathepsins. Our data support a mechanism in which
tumors acquire resistance to MMPIs by employing another type of
protease activity, contingent on a change in the spectrum and
abundance of tumor-promoting inﬂammatory cells and hence of
the proteases they supply. In such cases, therapeutic targeting of
both families of proteases might prove efﬁcacious, by obviating
the demonstrable adaptive resistance to MMPIs.
MATERIALS AND METHODS
Mice, tissue sample generation, manipulation and preparation
All mice were housed, fed and treated in accordance with protocols
approved by the committee for animal research at the University of
California, San Francisco, CA, USA. The RT2 mouse model of pancreatic islet
cell carcinogenesis and transgenic mice expressing switchable MycERTAM
and constitutive Bcl-xL in their pancreatic b cells pIns-MycER
TAMRIP7-Bcl-xL
(Myc;BclXl) mice have been previously described and characterized.13,20
MycERTAM was activated in b cells in situ by daily intraperitoneal injection
of tamoxifen (TAM) (1mg/mouse/day) dissolved in peanut oil (Sigma,
St Louis, MO, USA). TAM is metabolized in vivo to 4-OHT and has an
equivalent effect to 4-OHT when administered to Myc;BclXl mice. The
MMP9-deﬁcient animals from C57BL/6 background were kindly provided
by Dr Z Werb (UCSF). Tissues were prepared as previously described for
frozen and parafﬁn embedding.67,21 The hematoxylin and eosin grading of
tumors was performed as described.67,68 At least 49 tumors for each
genotype were analyzed. Analysis of tumor circularity was performed with
the Fiji Software package (http://rsb.info.nih.gov/ij). The method is
described as follows. Serial hematoxylin and eosin-stained sections of
the entire pancreata from the tumor-bearing animals were scanned with a
Leica DM5500 (Wetzlar, Germany) at  20 magniﬁcation. The software
then takes a manually outlined tumor border, and outputs a coefﬁcient of
circularity which varies between 0 and 1, where 1 denotes prefect
circularity. At least 23 tumors for each genotype were analyzed. The
Loss of metalloproteinase 9 promotes tumor invasion
K Shchors et al
9
Oncogene (2012), 1 - 12& 2012 Macmillan Publishers Limited
characterization of islet and tumor vasculature, and inhibition of systemic
IL-1b in vivo were performed as described.21
Isolation of pancreatic islets and in vitro analysis
To assay VEGF-A release, the ﬁbrinogen-embedded islets isolated from
pancreata21 were cultured for 48h in the presence of either 100nM 4-OHT or
carrier in conjuction with pan-MMPI GM6001 (20mM) (Chemicon, Temecula, CA,
USA) or equal volume of control vehicle dimethylsulphoxide. The conditioned
medium was collected and assayed for VEGF-A by Super-ELISA (Biotraces, Inc.,
Herndon, VA, USA) according to proprietary protocol. For substrate conversion
assay or substrate zymography, the pancreata from Myc;BclXl and BclXl mice
was isolated omitting digestion with collagens P and analyzed directly.
Substrate conversion assay and zymography
Freshly isolated pancreatic islets from the Myc;BcXL mice daily treated with
4-OHT or control vehicle for 3 days were lysed in solubilization buffer
(25mM Tris (pH 7.6), 0.25% Triton X-100, 5mM CaCl2). Protein concentration
was determined by the Bio-Rad DC (Hercules, CA, USA). Substrate
conversion assay and application of MMPI 1,10 phenanthroline (Sigma)
was carried out as described.69 Fluorescence measurements were
performed using a microplate spectroﬂuorometer (SpectraMax Gemini
EM, Molecular Devices, Sunnyvale, CA, USA) operated by SoftMax Pro 4.1
software. Values shown represent the mean±s.e.m. from three indepen-
dent islet isolations of analyses performed in triplicate.
Equivalent amount of protein extract was analyzed by gelatin
zymography70 on 10% sodium dodecyl sulfate (SDS) - polyacrylamide gels
co-polymerase with substrate (1.2mg/ml of gelatin) in sample buffer (2%
SDS, 50mM Tris-HCl, 10% glycerol, 0.1% Bromphenol blue, pH6.8), washed
in 2.5% Triton X-100 for 30min, then in ddH2O for 15min, and incubated at
37 1C overnight in collagenase buffer (50mM Tris-HCl, 10mM CaCl2, 200mM
NaCl) supplemented with 0.02% v/v Bruj. Next day, the gel was subjected
to Coomassie blue staining/destaining procedure. Negative staining
indicates the location of active protease bands. Exposure of pro-enzymes
within tissue extracts to SDS during the gel separation procedure leads to
activation without proteolytic cleavage.71
Histology and immunoﬂuorescence
In all, 10mm OCT-embedded tissue sections were ﬁxed in 1% paraformal-
dehyde. The primary antibodies used: anti-mouse VEGF-A (70R-VR001x,
Fitzgerald, Acton, MA, USA), anti-Meca-32 (550 563, BD Pharmingen, San
Diego, CA, USA), anti-Ki67 (ab16 667, Abcam, Cambridge, UK), anti-murine
CD45 (550 539, BD Pharmingen), anti-murine CD4 (14-0042-81,
eBioscience, Vienna, Austria), anti-murine Ly-6G (Gr-1) (14-5931-81,
eBioscience), phycoerythrin-conjugated CD11b (Mac-1) (557 397, BD
Pharmingen), anti-murine CD68 (MCA1957, Serotec, Du¨sseldorf, Germany),
anti-murine F4/80 (MCA497G, Serotec), anti-murine cathepsin B (AF965,
R&D Systems, Minneapolis, MN, USA), anti-Glut1 (ab652, Abcam) and anti-
murine MMP9 antibodies (gift of Dr Z Werb (UCSF)).
All were applied in blocking buffer (2.5% bovine serum albumin, 5%
donkey serum) for 2 - 16 h. Secondary antibodies were from Dako (Baar,
Switzerland) and Molecular Probes (Life Technologies Europe B.V., Zug,
Switzerland). Fluorescent images were obtained using Leica DM5500 or, for
confocal imagery, Zeiss LSM 700 (PT-BIOP (EPFL)). Immunohistochemical
analysis for each antigen was performed at least in duplicate.
Endothelial cell proliferation was quantiﬁed in tissue sections by
counting randomized ﬁelds of endothelial cells (Meca32þ ) and calculating
the percentage of Ki67þ cells. At least three animals were assayed of each
genotype all analyses done in duplicate; 10 randomized ﬁelds per analysis
were considered. Statistical signiﬁcance was assessed using the Student’s
t-test. The minimum level of signiﬁcance was set at Pp0.001.
Analysis of cathepsin activity
The collected tumors were homogenized on ice in lysis buffer (50mM
acetate buffer (pH 5.5), 5mM dithiothreitol, 5mM MgCl2, 0.1% Triton X-100).
Protein concentration was established by the Bradford assay. The equal
amount of protein lysates were labeled with biotinylated DCG-04 ABP27
for a ﬁnal concentration 1 mm, equally loaded, separated by SDS-
polyacrylamide gel electrophoresis, and transferred onto polyvinylidine
ﬂuoride membranes (Roche, Rotkreuz, Switzerland). The cysteine cathe-
psins activity was determined by incubation with horseradish peroxidase-
conjugated streptavidin (Invitrogen, Carlsbad, CA, USA).
Western blot analysis
The tumors were lysed in buffer (50mM Tris, pH 7.4; 150mM NaCl, 1%
NP-40, 0.1% SDS) containing protease inhibitor (Complete Mini, EDTA-free)
and phosphates inhibitors (PhosSTOP) (Roche). Equal amounts of proteins
were separated by SDS- polyacrylamide gel electrophoresis and transferred
onto polyvinylidine ﬂuoride membranes. Primary antibodies used were as
follows: cathepsin B (AF965), cathepsin S (AF1183), cathepsin C (AF1034) (R&D
Systems), neutrophil elastase (sc-9521, Santa Cruz, Santa Cruz, CA, USA), anti-b-
actin (A2228, Sigma). All secondary antibodies were from Jackson ImmunoR-
esearch Laboratories (West Grove, PA, USA). The quantiﬁcation of cathepsin
expression was determined by Gel Analysis with Fiji package software.
Statistical analysis
Fisher’s exact test and the w2 test were used to compare tumor invasion
metrics via the Prism software package (GraphPad Prism 5 Software,
La Jolla, CA, USA). A P-value of Pp0.02 was considered signiﬁcant.
Student’s t-test analysis was used to compare tumor circularity. To
compare the proﬁle of inﬂammatory cells recruited to the tumor sites, a
minimum of 35 tumors per group were analyzed. The immune cells were
quantiﬁed in whole tumor sections and expressed as a percentage of total
cells. Student’s t-test analysis was performed with Prism software package
(La Jolla, CA, USA). A P-value of Pp0.01 was considered signiﬁcant.
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